AUSTIN, Texas, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative,...
WALTHAM, Mass. and BOULDER, Colo., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on...
Study provides additional support for further evaluation of TransCode’s lead therapeutic candidate, TTX-MC138, in clinical trialsBOSTON, Oct. 26, 2022 (GLOBE...
Initial Phase 1 data of FHD-609 show degradation of BRD9 in on-treatment metastatic tumor synovial sarcoma biopsies New preclinical data...
Complete response observed and ongoing in a patient with multiply relapsed/refractory diffuse large B cell lymphoma (DLBCL) Dual BTK degradation...
-WDS improves industrial tomato yield, creating meaningful increase amid harsh weather conditions -REHOVOT, Israel, Oct. 26, 2022 (GLOBE NEWSWIRE) --...
PRESS RELEASE VacV Biotherapeutics emerges from stealth mode to bring ground-breaking cancer immunotherapies to the clinic Enhanced systemic delivery system...
PETACH TIKVA, Israel, Oct. 26, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company...
WATERTOWN, Mass., Oct. 26, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and...
Study results show a low 2.6% recurrence rate and clinically meaningful improvement in patient quality of lifeMALVERN, Pa., Oct. 26,...
Amended Bridging Pharmacokinetics Study for Autosomal Dominant Polycystic Kidney Disease – XRx-008 ProgramCALGARY, Alberta, Oct. 26, 2022 (GLOBE NEWSWIRE) --...